nodes	percent_of_prediction	percent_of_DWPC	metapath
Linagliptin—ABCB1—ovarian cancer	0.5	1	CbGaD
Linagliptin—ABCB1—Topotecan—ovarian cancer	0.0825	0.221	CbGbCtD
Linagliptin—ABCB1—Vinorelbine—ovarian cancer	0.0581	0.156	CbGbCtD
Linagliptin—CYP3A4—Topotecan—ovarian cancer	0.0494	0.133	CbGbCtD
Linagliptin—ABCB1—Paclitaxel—ovarian cancer	0.0408	0.11	CbGbCtD
Linagliptin—CYP3A4—Vinorelbine—ovarian cancer	0.0348	0.0935	CbGbCtD
Linagliptin—ABCB1—Docetaxel—ovarian cancer	0.0295	0.0793	CbGbCtD
Linagliptin—CYP3A4—Paclitaxel—ovarian cancer	0.0245	0.0657	CbGbCtD
Linagliptin—ABCB1—Doxorubicin—ovarian cancer	0.022	0.0591	CbGbCtD
Linagliptin—CYP3A4—Docetaxel—ovarian cancer	0.0177	0.0475	CbGbCtD
Linagliptin—CYP3A4—Doxorubicin—ovarian cancer	0.0132	0.0354	CbGbCtD
Linagliptin—DPP4—embryo—ovarian cancer	0.00342	0.0966	CbGeAlD
Linagliptin—DPP4—epithelium—ovarian cancer	0.00279	0.0789	CbGeAlD
Linagliptin—DPP4—uterine cervix—ovarian cancer	0.00277	0.0782	CbGeAlD
Linagliptin—DPP4—decidua—ovarian cancer	0.00264	0.0745	CbGeAlD
Linagliptin—DPP4—endometrium—ovarian cancer	0.0025	0.0707	CbGeAlD
Linagliptin—Pancreatitis acute—Paclitaxel—ovarian cancer	0.00232	0.025	CcSEcCtD
Linagliptin—DPP4—uterus—ovarian cancer	0.00231	0.0652	CbGeAlD
Linagliptin—DPP4—female reproductive system—ovarian cancer	0.00207	0.0586	CbGeAlD
Linagliptin—DPP4—bone marrow—ovarian cancer	0.00196	0.0553	CbGeAlD
Linagliptin—DPP4—female gonad—ovarian cancer	0.00189	0.0533	CbGeAlD
Linagliptin—DPP4—vagina—ovarian cancer	0.00187	0.053	CbGeAlD
Linagliptin—Skin exfoliation—Melphalan—ovarian cancer	0.00174	0.0188	CcSEcCtD
Linagliptin—DPP4—testis—ovarian cancer	0.00167	0.0473	CbGeAlD
Linagliptin—Skin exfoliation—Vinorelbine—ovarian cancer	0.00152	0.0164	CcSEcCtD
Linagliptin—Infection—Carboplatin—ovarian cancer	0.00144	0.0155	CcSEcCtD
Linagliptin—DPP4—lymph node—ovarian cancer	0.00121	0.0343	CbGeAlD
Linagliptin—Weight increased—Topotecan—ovarian cancer	0.00106	0.0115	CcSEcCtD
Linagliptin—Infestation NOS—Topotecan—ovarian cancer	0.00104	0.0112	CcSEcCtD
Linagliptin—Infestation—Topotecan—ovarian cancer	0.00104	0.0112	CcSEcCtD
Linagliptin—Skin exfoliation—Paclitaxel—ovarian cancer	0.00102	0.011	CcSEcCtD
Linagliptin—Pancreatitis—Vinorelbine—ovarian cancer	0.000978	0.0106	CcSEcCtD
Linagliptin—Infestation NOS—Vinorelbine—ovarian cancer	0.00089	0.00961	CcSEcCtD
Linagliptin—Infestation—Vinorelbine—ovarian cancer	0.00089	0.00961	CcSEcCtD
Linagliptin—Skin exfoliation—Docetaxel—ovarian cancer	0.000866	0.00935	CcSEcCtD
Linagliptin—Hyperlipidaemia—Epirubicin—ovarian cancer	0.000849	0.00916	CcSEcCtD
Linagliptin—Immune system disorder—Topotecan—ovarian cancer	0.000843	0.0091	CcSEcCtD
Linagliptin—Mediastinal disorder—Topotecan—ovarian cancer	0.000842	0.00908	CcSEcCtD
Linagliptin—Angioedema—Chlorambucil—ovarian cancer	0.000834	0.00901	CcSEcCtD
Linagliptin—Immune system disorder—Melphalan—ovarian cancer	0.000826	0.00891	CcSEcCtD
Linagliptin—Mediastinal disorder—Melphalan—ovarian cancer	0.000824	0.0089	CcSEcCtD
Linagliptin—ABCB1—myometrium—ovarian cancer	0.000821	0.0232	CbGeAlD
Linagliptin—Malnutrition—Topotecan—ovarian cancer	0.000813	0.00877	CcSEcCtD
Linagliptin—Hypoglycaemia—Paclitaxel—ovarian cancer	0.000796	0.00859	CcSEcCtD
Linagliptin—ABCB1—embryo—ovarian cancer	0.000789	0.0223	CbGeAlD
Linagliptin—Back pain—Topotecan—ovarian cancer	0.000786	0.00849	CcSEcCtD
Linagliptin—Hyperlipidaemia—Doxorubicin—ovarian cancer	0.000785	0.00848	CcSEcCtD
Linagliptin—Pain in extremity—Paclitaxel—ovarian cancer	0.000777	0.00838	CcSEcCtD
Linagliptin—Angioedema—Topotecan—ovarian cancer	0.000743	0.00802	CcSEcCtD
Linagliptin—Infection—Chlorambucil—ovarian cancer	0.00074	0.00799	CcSEcCtD
Linagliptin—Immune system disorder—Vinorelbine—ovarian cancer	0.000722	0.00779	CcSEcCtD
Linagliptin—Mediastinal disorder—Vinorelbine—ovarian cancer	0.00072	0.00777	CcSEcCtD
Linagliptin—Cough—Topotecan—ovarian cancer	0.000709	0.00766	CcSEcCtD
Linagliptin—Malnutrition—Vinorelbine—ovarian cancer	0.000695	0.00751	CcSEcCtD
Linagliptin—Cough—Melphalan—ovarian cancer	0.000695	0.0075	CcSEcCtD
Linagliptin—Nasopharyngitis—Paclitaxel—ovarian cancer	0.000695	0.0075	CcSEcCtD
Linagliptin—Arthralgia—Topotecan—ovarian cancer	0.000692	0.00747	CcSEcCtD
Linagliptin—Myalgia—Topotecan—ovarian cancer	0.000692	0.00747	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Topotecan—ovarian cancer	0.000687	0.00742	CcSEcCtD
Linagliptin—Myalgia—Melphalan—ovarian cancer	0.000678	0.00731	CcSEcCtD
Linagliptin—CYP3A4—female reproductive system—ovarian cancer	0.000676	0.0191	CbGeAlD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Melphalan—ovarian cancer	0.000673	0.00726	CcSEcCtD
Linagliptin—Back pain—Vinorelbine—ovarian cancer	0.000673	0.00726	CcSEcCtD
Linagliptin—Anaphylactic shock—Topotecan—ovarian cancer	0.000663	0.00716	CcSEcCtD
Linagliptin—Infection—Topotecan—ovarian cancer	0.000659	0.00711	CcSEcCtD
Linagliptin—Pain in extremity—Docetaxel—ovarian cancer	0.000658	0.00711	CcSEcCtD
Linagliptin—Pancreatitis—Paclitaxel—ovarian cancer	0.000658	0.0071	CcSEcCtD
Linagliptin—Anaphylactic shock—Melphalan—ovarian cancer	0.00065	0.00701	CcSEcCtD
Linagliptin—Infection—Melphalan—ovarian cancer	0.000645	0.00697	CcSEcCtD
Linagliptin—Skin disorder—Topotecan—ovarian cancer	0.000644	0.00696	CcSEcCtD
Linagliptin—ABCB1—epithelium—ovarian cancer	0.000644	0.0182	CbGeAlD
Linagliptin—Gastrointestinal disorder—Chlorambucil—ovarian cancer	0.000643	0.00695	CcSEcCtD
Linagliptin—ABCB1—uterine cervix—ovarian cancer	0.000639	0.018	CbGeAlD
Linagliptin—Angioedema—Vinorelbine—ovarian cancer	0.000635	0.00686	CcSEcCtD
Linagliptin—Skin disorder—Melphalan—ovarian cancer	0.000631	0.00681	CcSEcCtD
Linagliptin—Upper respiratory tract infection—Paclitaxel—ovarian cancer	0.000624	0.00673	CcSEcCtD
Linagliptin—Weight increased—Paclitaxel—ovarian cancer	0.000611	0.00659	CcSEcCtD
Linagliptin—ABCB1—decidua—ovarian cancer	0.000609	0.0172	CbGeAlD
Linagliptin—Cough—Vinorelbine—ovarian cancer	0.000607	0.00655	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Topotecan—ovarian cancer	0.000604	0.00652	CcSEcCtD
Linagliptin—Infestation NOS—Paclitaxel—ovarian cancer	0.000599	0.00646	CcSEcCtD
Linagliptin—Infestation—Paclitaxel—ovarian cancer	0.000599	0.00646	CcSEcCtD
Linagliptin—Urticaria—Chlorambucil—ovarian cancer	0.000592	0.00639	CcSEcCtD
Linagliptin—Arthralgia—Vinorelbine—ovarian cancer	0.000592	0.00639	CcSEcCtD
Linagliptin—Myalgia—Vinorelbine—ovarian cancer	0.000592	0.00639	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Melphalan—ovarian cancer	0.000592	0.00639	CcSEcCtD
Linagliptin—Nasopharyngitis—Docetaxel—ovarian cancer	0.000589	0.00635	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Vinorelbine—ovarian cancer	0.000588	0.00635	CcSEcCtD
Linagliptin—Skin exfoliation—Epirubicin—ovarian cancer	0.000584	0.0063	CcSEcCtD
Linagliptin—Urinary tract infection—Paclitaxel—ovarian cancer	0.000582	0.00628	CcSEcCtD
Linagliptin—ABCB1—endometrium—ovarian cancer	0.000578	0.0163	CbGeAlD
Linagliptin—Gastrointestinal disorder—Topotecan—ovarian cancer	0.000573	0.00618	CcSEcCtD
Linagliptin—Anaphylactic shock—Vinorelbine—ovarian cancer	0.000568	0.00613	CcSEcCtD
Linagliptin—Constipation—Topotecan—ovarian cancer	0.000567	0.00612	CcSEcCtD
Linagliptin—Infection—Vinorelbine—ovarian cancer	0.000564	0.00609	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Melphalan—ovarian cancer	0.000561	0.00605	CcSEcCtD
Linagliptin—Skin disorder—Vinorelbine—ovarian cancer	0.000551	0.00595	CcSEcCtD
Linagliptin—Hypersensitivity—Chlorambucil—ovarian cancer	0.000549	0.00593	CcSEcCtD
Linagliptin—Skin exfoliation—Doxorubicin—ovarian cancer	0.00054	0.00583	CcSEcCtD
Linagliptin—ABCB1—gonad—ovarian cancer	0.000536	0.0151	CbGeAlD
Linagliptin—ABCB1—uterus—ovarian cancer	0.000532	0.015	CbGeAlD
Linagliptin—Urticaria—Topotecan—ovarian cancer	0.000527	0.00569	CcSEcCtD
Linagliptin—Weight increased—Docetaxel—ovarian cancer	0.000518	0.00559	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Vinorelbine—ovarian cancer	0.000517	0.00558	CcSEcCtD
Linagliptin—Urticaria—Melphalan—ovarian cancer	0.000516	0.00557	CcSEcCtD
Linagliptin—Diabetes mellitus—Epirubicin—ovarian cancer	0.000511	0.00551	CcSEcCtD
Linagliptin—Diarrhoea—Chlorambucil—ovarian cancer	0.00051	0.0055	CcSEcCtD
Linagliptin—Infestation NOS—Docetaxel—ovarian cancer	0.000507	0.00548	CcSEcCtD
Linagliptin—Infestation—Docetaxel—ovarian cancer	0.000507	0.00548	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Vinorelbine—ovarian cancer	0.00049	0.00529	CcSEcCtD
Linagliptin—Hypersensitivity—Topotecan—ovarian cancer	0.000489	0.00528	CcSEcCtD
Linagliptin—Constipation—Vinorelbine—ovarian cancer	0.000485	0.00524	CcSEcCtD
Linagliptin—Immune system disorder—Paclitaxel—ovarian cancer	0.000485	0.00524	CcSEcCtD
Linagliptin—Mediastinal disorder—Paclitaxel—ovarian cancer	0.000484	0.00523	CcSEcCtD
Linagliptin—Hypersensitivity—Melphalan—ovarian cancer	0.000479	0.00517	CcSEcCtD
Linagliptin—ABCB1—female reproductive system—ovarian cancer	0.000479	0.0135	CbGeAlD
Linagliptin—Diabetes mellitus—Doxorubicin—ovarian cancer	0.000472	0.0051	CcSEcCtD
Linagliptin—Malnutrition—Paclitaxel—ovarian cancer	0.000468	0.00505	CcSEcCtD
Linagliptin—Hypoglycaemia—Epirubicin—ovarian cancer	0.000455	0.00491	CcSEcCtD
Linagliptin—Diarrhoea—Topotecan—ovarian cancer	0.000454	0.0049	CcSEcCtD
Linagliptin—Back pain—Paclitaxel—ovarian cancer	0.000452	0.00488	CcSEcCtD
Linagliptin—ABCB1—bone marrow—ovarian cancer	0.000452	0.0128	CbGeAlD
Linagliptin—Urticaria—Vinorelbine—ovarian cancer	0.000451	0.00487	CcSEcCtD
Linagliptin—Diarrhoea—Melphalan—ovarian cancer	0.000444	0.0048	CcSEcCtD
Linagliptin—Pain in extremity—Epirubicin—ovarian cancer	0.000444	0.00479	CcSEcCtD
Linagliptin—ABCB1—female gonad—ovarian cancer	0.000435	0.0123	CbGeAlD
Linagliptin—ABCB1—vagina—ovarian cancer	0.000433	0.0122	CbGeAlD
Linagliptin—Angioedema—Paclitaxel—ovarian cancer	0.000427	0.00461	CcSEcCtD
Linagliptin—Hypoglycaemia—Doxorubicin—ovarian cancer	0.000421	0.00454	CcSEcCtD
Linagliptin—Rash—Topotecan—ovarian cancer	0.000418	0.00452	CcSEcCtD
Linagliptin—Hypersensitivity—Vinorelbine—ovarian cancer	0.000418	0.00451	CcSEcCtD
Linagliptin—Dermatitis—Topotecan—ovarian cancer	0.000418	0.00451	CcSEcCtD
Linagliptin—Headache—Topotecan—ovarian cancer	0.000416	0.00449	CcSEcCtD
Linagliptin—Immune system disorder—Docetaxel—ovarian cancer	0.000411	0.00444	CcSEcCtD
Linagliptin—Pain in extremity—Doxorubicin—ovarian cancer	0.000411	0.00443	CcSEcCtD
Linagliptin—Mediastinal disorder—Docetaxel—ovarian cancer	0.00041	0.00443	CcSEcCtD
Linagliptin—Rash—Melphalan—ovarian cancer	0.00041	0.00442	CcSEcCtD
Linagliptin—Dermatitis—Melphalan—ovarian cancer	0.000409	0.00442	CcSEcCtD
Linagliptin—Cough—Paclitaxel—ovarian cancer	0.000408	0.00441	CcSEcCtD
Linagliptin—Myalgia—Paclitaxel—ovarian cancer	0.000398	0.0043	CcSEcCtD
Linagliptin—Arthralgia—Paclitaxel—ovarian cancer	0.000398	0.0043	CcSEcCtD
Linagliptin—Nasopharyngitis—Epirubicin—ovarian cancer	0.000397	0.00429	CcSEcCtD
Linagliptin—Malnutrition—Docetaxel—ovarian cancer	0.000396	0.00428	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—ovarian cancer	0.000395	0.00427	CcSEcCtD
Linagliptin—Diarrhoea—Vinorelbine—ovarian cancer	0.000388	0.00419	CcSEcCtD
Linagliptin—ABCB1—testis—ovarian cancer	0.000386	0.0109	CbGeAlD
Linagliptin—Back pain—Docetaxel—ovarian cancer	0.000383	0.00414	CcSEcCtD
Linagliptin—Anaphylactic shock—Paclitaxel—ovarian cancer	0.000382	0.00412	CcSEcCtD
Linagliptin—Infection—Paclitaxel—ovarian cancer	0.000379	0.00409	CcSEcCtD
Linagliptin—Pancreatitis—Epirubicin—ovarian cancer	0.000376	0.00406	CcSEcCtD
Linagliptin—Skin disorder—Paclitaxel—ovarian cancer	0.000371	0.004	CcSEcCtD
Linagliptin—Nasopharyngitis—Doxorubicin—ovarian cancer	0.000367	0.00397	CcSEcCtD
Linagliptin—Rash—Vinorelbine—ovarian cancer	0.000358	0.00386	CcSEcCtD
Linagliptin—Dermatitis—Vinorelbine—ovarian cancer	0.000358	0.00386	CcSEcCtD
Linagliptin—Upper respiratory tract infection—Epirubicin—ovarian cancer	0.000357	0.00385	CcSEcCtD
Linagliptin—Headache—Vinorelbine—ovarian cancer	0.000356	0.00384	CcSEcCtD
Linagliptin—Weight increased—Epirubicin—ovarian cancer	0.000349	0.00377	CcSEcCtD
Linagliptin—Pancreatitis—Doxorubicin—ovarian cancer	0.000348	0.00376	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	0.000348	0.00375	CcSEcCtD
Linagliptin—Cough—Docetaxel—ovarian cancer	0.000346	0.00373	CcSEcCtD
Linagliptin—Infestation NOS—Epirubicin—ovarian cancer	0.000342	0.00369	CcSEcCtD
Linagliptin—Infestation—Epirubicin—ovarian cancer	0.000342	0.00369	CcSEcCtD
Linagliptin—Myalgia—Docetaxel—ovarian cancer	0.000338	0.00364	CcSEcCtD
Linagliptin—Arthralgia—Docetaxel—ovarian cancer	0.000338	0.00364	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.000335	0.00362	CcSEcCtD
Linagliptin—Urinary tract infection—Epirubicin—ovarian cancer	0.000333	0.00359	CcSEcCtD
Linagliptin—Upper respiratory tract infection—Doxorubicin—ovarian cancer	0.00033	0.00356	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.00033	0.00356	CcSEcCtD
Linagliptin—Constipation—Paclitaxel—ovarian cancer	0.000326	0.00352	CcSEcCtD
Linagliptin—Anaphylactic shock—Docetaxel—ovarian cancer	0.000324	0.00349	CcSEcCtD
Linagliptin—Weight increased—Doxorubicin—ovarian cancer	0.000323	0.00349	CcSEcCtD
Linagliptin—Infection—Docetaxel—ovarian cancer	0.000321	0.00347	CcSEcCtD
Linagliptin—Infestation NOS—Doxorubicin—ovarian cancer	0.000317	0.00342	CcSEcCtD
Linagliptin—Infestation—Doxorubicin—ovarian cancer	0.000317	0.00342	CcSEcCtD
Linagliptin—Skin disorder—Docetaxel—ovarian cancer	0.000314	0.00339	CcSEcCtD
Linagliptin—Urinary tract infection—Doxorubicin—ovarian cancer	0.000308	0.00332	CcSEcCtD
Linagliptin—Urticaria—Paclitaxel—ovarian cancer	0.000303	0.00327	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Docetaxel—ovarian cancer	0.000295	0.00318	CcSEcCtD
Linagliptin—Hypersensitivity—Paclitaxel—ovarian cancer	0.000281	0.00304	CcSEcCtD
Linagliptin—ABCB1—lymph node—ovarian cancer	0.00028	0.00791	CbGeAlD
Linagliptin—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.000279	0.00302	CcSEcCtD
Linagliptin—Immune system disorder—Epirubicin—ovarian cancer	0.000277	0.003	CcSEcCtD
Linagliptin—Mediastinal disorder—Epirubicin—ovarian cancer	0.000277	0.00299	CcSEcCtD
Linagliptin—Constipation—Docetaxel—ovarian cancer	0.000277	0.00299	CcSEcCtD
Linagliptin—Malnutrition—Epirubicin—ovarian cancer	0.000267	0.00289	CcSEcCtD
Linagliptin—Diarrhoea—Paclitaxel—ovarian cancer	0.000261	0.00282	CcSEcCtD
Linagliptin—Back pain—Epirubicin—ovarian cancer	0.000259	0.00279	CcSEcCtD
Linagliptin—Immune system disorder—Doxorubicin—ovarian cancer	0.000257	0.00277	CcSEcCtD
Linagliptin—Mediastinal disorder—Doxorubicin—ovarian cancer	0.000256	0.00277	CcSEcCtD
Linagliptin—Malnutrition—Doxorubicin—ovarian cancer	0.000247	0.00267	CcSEcCtD
Linagliptin—Rash—Paclitaxel—ovarian cancer	0.000241	0.0026	CcSEcCtD
Linagliptin—Dermatitis—Paclitaxel—ovarian cancer	0.00024	0.0026	CcSEcCtD
Linagliptin—Back pain—Doxorubicin—ovarian cancer	0.000239	0.00258	CcSEcCtD
Linagliptin—Headache—Paclitaxel—ovarian cancer	0.000239	0.00258	CcSEcCtD
Linagliptin—Hypersensitivity—Docetaxel—ovarian cancer	0.000238	0.00257	CcSEcCtD
Linagliptin—Cough—Epirubicin—ovarian cancer	0.000233	0.00252	CcSEcCtD
Linagliptin—Arthralgia—Epirubicin—ovarian cancer	0.000228	0.00246	CcSEcCtD
Linagliptin—Myalgia—Epirubicin—ovarian cancer	0.000228	0.00246	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	0.000226	0.00244	CcSEcCtD
Linagliptin—Diarrhoea—Docetaxel—ovarian cancer	0.000221	0.00239	CcSEcCtD
Linagliptin—Anaphylactic shock—Epirubicin—ovarian cancer	0.000218	0.00236	CcSEcCtD
Linagliptin—Infection—Epirubicin—ovarian cancer	0.000217	0.00234	CcSEcCtD
Linagliptin—Cough—Doxorubicin—ovarian cancer	0.000216	0.00233	CcSEcCtD
Linagliptin—Skin disorder—Epirubicin—ovarian cancer	0.000212	0.00229	CcSEcCtD
Linagliptin—Arthralgia—Doxorubicin—ovarian cancer	0.000211	0.00227	CcSEcCtD
Linagliptin—Myalgia—Doxorubicin—ovarian cancer	0.000211	0.00227	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	0.000209	0.00226	CcSEcCtD
Linagliptin—Rash—Docetaxel—ovarian cancer	0.000204	0.0022	CcSEcCtD
Linagliptin—Dermatitis—Docetaxel—ovarian cancer	0.000204	0.0022	CcSEcCtD
Linagliptin—Headache—Docetaxel—ovarian cancer	0.000203	0.00219	CcSEcCtD
Linagliptin—Anaphylactic shock—Doxorubicin—ovarian cancer	0.000202	0.00218	CcSEcCtD
Linagliptin—Infection—Doxorubicin—ovarian cancer	0.000201	0.00217	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Epirubicin—ovarian cancer	0.000199	0.00215	CcSEcCtD
Linagliptin—Skin disorder—Doxorubicin—ovarian cancer	0.000196	0.00212	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.000188	0.00203	CcSEcCtD
Linagliptin—Constipation—Epirubicin—ovarian cancer	0.000187	0.00201	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	0.000184	0.00199	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Doxorubicin—ovarian cancer	0.000174	0.00188	CcSEcCtD
Linagliptin—Urticaria—Epirubicin—ovarian cancer	0.000173	0.00187	CcSEcCtD
Linagliptin—Constipation—Doxorubicin—ovarian cancer	0.000173	0.00186	CcSEcCtD
Linagliptin—Hypersensitivity—Epirubicin—ovarian cancer	0.000161	0.00174	CcSEcCtD
Linagliptin—Urticaria—Doxorubicin—ovarian cancer	0.00016	0.00173	CcSEcCtD
Linagliptin—Diarrhoea—Epirubicin—ovarian cancer	0.000149	0.00161	CcSEcCtD
Linagliptin—Hypersensitivity—Doxorubicin—ovarian cancer	0.000149	0.00161	CcSEcCtD
Linagliptin—Diarrhoea—Doxorubicin—ovarian cancer	0.000138	0.00149	CcSEcCtD
Linagliptin—Rash—Epirubicin—ovarian cancer	0.000138	0.00149	CcSEcCtD
Linagliptin—Dermatitis—Epirubicin—ovarian cancer	0.000137	0.00148	CcSEcCtD
Linagliptin—Headache—Epirubicin—ovarian cancer	0.000137	0.00148	CcSEcCtD
Linagliptin—Rash—Doxorubicin—ovarian cancer	0.000127	0.00137	CcSEcCtD
Linagliptin—Dermatitis—Doxorubicin—ovarian cancer	0.000127	0.00137	CcSEcCtD
Linagliptin—Headache—Doxorubicin—ovarian cancer	0.000127	0.00137	CcSEcCtD
